CardioMetAge deviation was strongly associated with cardiometabolic disease mortality (HR 1.87 per SD) and outperformed traditional biological age models in predicting 10-year disease incidence.
Cohort (n=463,125)
Yes
Does CardioMetAge improve the prediction of CMD-related outcomes compared to existing aging clocks?
CardioMetAge is a novel aging clock that outperforms existing tools in predicting cardiometabolic disease outcomes, offering potential for clinical monitoring.
Hazard Ratio: 1.87 (95% CI 1.83–1.91)
CardioMetAge outperformed existing aging clocks in ease of use and in predicting CMD-related outcomes. It provides valuable insights into the mechanisms of cardiometabolic aging and holds potential for clinical monitoring and evaluating the effectiveness of interventions.
Li et al. (Sat,) conducted a cohort in Cardiometabolic diseases (n=463,125). CardioMetAge deviation (CardioMetAgeDev) vs. Per 1 standard deviation increase was evaluated on Cardiometabolic disease mortality (HR 1.87, 95% CI 1.83-1.91). CardioMetAge deviation was strongly associated with cardiometabolic disease mortality (HR 1.87 per SD) and outperformed traditional biological age models in predicting 10-year disease incidence.